Sign Up and Stay connected to us

Track and monitor the latest market updates, launches and upcoming market entrants, news of Indian regulatory affairs and our fresh service offerings- to revamp your business strategies, combat competition and stay differentiated in the highly evolving and dynamic Indian market. Have the power, delivered to your inbox, every month. The newsletter will keep you cognizant about our latest offers and best deals on availing specific services. Your contact details and email are strictly secured with us. Please feel free to send across your queries according to your business needs.

Competitive Advantage

In today’s dynamic and ever-evolving market, you need competitive intelligence to sustain your competitive advantage and stay differentiated from competitors. If your competitors have better edge than you, you need to know why. If you are winning, you need to check your rear view mirror.Our competitive intelligence portfolio helps understand and monitor your competitors better. Using exhaustive secondary desk-research, primary market research, and qualitative and quantitative analytics, Admirus delivers best factual, customised competitive intelligence reports possible.

Advantages from Admirus competitive intelligence portfolio

Utilizing our balanced blend of scientific and market knowledge with business analytics expertise, you can get benefit from the following array of analyses related to CI:


  • Therapy Area Landscape/Market Assessment:

    Disease Overview; Treatment Overview (Guidelines, Algorithm, Standard of Care); Pipeline Analysis; Unmet Medical Needs; Commercial opportunities

  • Competitive Landscape:

    Competitor marketing and pricing strategies; Financial performances of listed and unlisted companies;Revenues by department; Pricing of flagship products;Market penetration strategies; Competitor activity tracking (News letters, GRID analysis and portal creation)

  • Pipeline Assessment:

    Identifying and trackingthe emerging therapies/molecules in clinical development (from Phase I through Phase III) for indication of interest; Evaluating their potential; Probability of regulatory and clinical success; Clinical trial analysis, benchmarking and roadmap; Pivot trial analysis and learning from failed trials; Upcoming product launches

  • MoA Analysis: Identifying emerging mechanism of action and pathways for new product development
  • Commercialization / Market Attractiveness Assessment: Competitor and portfolio analysis (Marketed products and companies); Scenario planning;Message recall assessment;Conference coverage; Discussion forum analysis;Commercial opportunities evaluation
  • Epidemiology Analysis: Estimation of target market size in terms of patients;Derivation of incidence, prevalence, drug treated patient pool, survival rate, mortality, etc. for different indications by geographiesof interest
  • Patent Analysis/ Generic Competition Analysis: Tracking patent expiry timelines of the blockbuster drugs, generic entries and generic erosion in various therapeutic markets
  • Market Entry Opportunity Analysis: Identifying the potential and order of entry for your key products into various geographies/countries of interest (based on the demographics, healthcare infrastructure and regulations, healthcare expenditure, patient population, compliance rate, etc. in those countries)
  • Business Development and Licensing Opportunity Assessments: Identifying in-licensing and out-licensing opportunities and the size of those opportunities; Evaluating partners of choice for strategic business agreements/deals
  • Data Analytics: Analysis with paid data base sources (such as, IMS, CAM, Evaluate Pharma etc.)- Numeric calculation of market size (by sales, prescription), top products/molecules, top drug classes, top players, market share, growth (CAGR), etc.
  • Key Opinion Leader (KOL) Identification and Monitoring: Identify, prioritize, profile and manage the top KOLs and rising stars by indication in different geographical location; Maintaining long term relationship with them